Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma

Takayo Ota; Noriyuki Masuda; Kaoru Matsui; Takao Yamada; Noriko Tanaka; Shunsuke Fujimoto; Masahiro Fukuoka

doi:10.2169/internalmedicine.2554-18

This article has now been updated. Please use the final version.

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma

Takayo Ota, Noriyuki Masuda, Kaoru Matsui, Takao Yamada, Noriko Tanaka, Shunsuke Fujimoto, Masahiro Fukuoka

Author information

Keywords: c-ROS oncogene 1, crizotinib, liver injury, desensitization

JOURNAL OPEN ACCESS Advance online publication

Article ID: 2554-18

DOI https://doi.org/10.2169/internalmedicine.2554-18

The final version of this article is now available: Vol. 58 (2019), No. 18 pp. 2651-2655

Details

Abstract

Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injury. The patient discontinued crizotinib after 34 days due to liver toxicity. Twenty-four days later, when transaminases and C reactive protein (CRP) were normalized, crizotinib was resumed using an oral desensitization method. The patient was successfully treated for manageable recurrence of liver injury and has been able to continue the treatment.

Corresponding author

Register with J-STAGE for free!